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Abstract
Background and Aims: Peripheral joint complaints [pJTC] and chronic back pain [CBP] are the most 
common extra-intestinal manifestations in patients with inflammatory bowel disease [IBD]. This 
prospective study evaluates variables associated with joint/back pain, including IBD disease activity.
Methods: IBD patients with back pain ≥ 3 months and/or peripheral joint pain/swelling [n = 155], 
and IBD patients without joint complaints [n = 100; controls], were followed for a period of 1 year. 
Patients were classified as having SpondyloArthritis [SpA] according to several sets of criteria. 
Statistical analysis included logistic regression models and linear mixed model analysis.
Results: Of the 155 patients with joint/back pain, 13 had chronic back pain, 80 peripheral joint 
complaints, and 62 axial and peripheral joint complaints. Smoking, female gender, and IBD 
disease activity were independently associated with IBD joint/back pain. The Assessment in 
Spondyloarthritis International Society criteria for axial and peripheral SpA were fulfilled in 
12.3% of patients, with 9.7% [n = 15] receiving a rheumatological diagnosis of arthritis. During the 
12-month follow-up, the majority of the patients reporting joint/back pain remained stable.
Conclusions: In our cohort, the majority of IBD patients reported joint/back pain and SpA was 
relatively common. To facilitate effective care, gastroenterologists should be aware of the various 
features of SpA to classify joint complaints and, by making use of an efficient referral algorithm, to 
refer CBP patients to the rheumatologist.
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Arthropathies are the most common extra-intestinal manifestations 
of inflammatory bowel disease [IBD], affecting approximately 30% 
of the patients.1,2 Symptoms may be debilitating and have a con-
siderable impact on quality of life.3,4 IBD-associated arthropathies 
can be divided into inflammatory and non-inflammatory joint pain 
and may involve both axial and peripheral joints. Non-inflammatory 
joint pain, or arthralgia, is one of the most common complaints in 
daily IBD practice, but has not yet been studied systematically.3 Joint 
and back pain [hereafter referred to as ‘joint/back pain’] are the most 
important clinical manifestations of IBD-associated arthropathies.
For the gastroenterologist, joint/back pain can be challenging 
symptoms to diagnose and many have difficulties in differentiating 
arthralgia from arthritis. Since gastroenterologists are, in general, 
unfamiliar with the diagnosis and management of joint/back pain, 
it seems warranted that IBD joint complaints should be classified 
according to existing rheumatological standards, thus allowing 
appropriate multidisciplinary management. Moreover, gastroen-
terologists mostly apply the Oxford criteria5 to classify peripheral 
joint complaints, based on two different types according to articu-
lar involvement. Type 1 [oligoarticular] peripheral arthritis includes 
patients with less than five joints involved, evidence of joint swelling, 
and acute but self-limiting attacks. Type 2 [polyarticular] peripheral 
arthritis includes patients with five or more symmetrical affected 
joints, joint swelling, and a chronic character. Although the Oxford 
criteria distinguish these two types of peripheral joint complaints, this 
classification has limited utility for the physician in daily clinical prac-
tice. More importantly, these criteria are only applicable to arthritis 
and not to arthralgia. Rheumatologists therefore generally ignore 
the Oxford criteria and classify arthritis associated with IBD within 
the group of SpondyloArthritis [SpA] disorders.6 SpA is a group of 
rheumatic diseases characterised by inflammation of the spine and 
the sacroiliac [SI] joints. This often results in pain and/or stiffness of 
the spine and neck. Inflammation may affect other regions besides, 
including the peripheral joints, tendons, eyes, skin, and/or gut.
In order to develop a multidisciplinary care pathway for IBD 
patients with joint complaints, we rigorously characterised periph-
eral joint complaints [pJTC] and chronic back pain [CBP] accord-
ing to SpA criteria sets. In addition, we sought to determine which 
variables were associated with the onset of IBD joint complaints and 
which predicted long-term outcome. With this aim in mind, we car-
ried out a prospective, longitudinal follow-up study of IBD patients 
with back pain and/or peripheral joint complaints.
2. Methods
2.1. Study population
From July 2009 to February 2010, all IBD patients visiting the 
IBD outpatient clinic of the department of Gastroenterology and 
Hepatology of the Leiden University Medical Center [LUMC], The 
Netherlands, were asked to complete a questionnaire to assess the 
presence of joint complaints. The questions concerned experience of: 
[1] CBP, defined as back pain for ≥ 3 months; [2] CBP for ≥ 3 months 
during the past year; [3] current pJTC [pain and/or joint swell-
ing]; and [4] pJTC during the past year. Patients with self-reported 
joint/back pain were then invited to attend the JOINT outpatient 
clinic, a multidisciplinary clinic dedicated to IBD patients with joint 
complaints. This clinic was jointly established by the Department 
of Gastroenterology and Hepatology and the Department of 
Rheumatology, with the aim of expanding knowledge of IBD 
joint complaints, especially in the area of diagnosis and medical 
management. Patients with evident joint swelling and/or radiologi-
cally proven sacroiliitis were directly referred for rheumatological 
care. All IBD patients without joint/back pain during the previous 
year served as controls, and were also invited to attend the multi 
disciplinary clinic. To avoid high inclusion rates influencing the qual-
ity of patient care, and since only one clinical researcher was able to 
perform physical and rheumatological examinations, inclusion was 
limited to 255 patients. The study was approved by the institutional 
medical ethical committee of the LUMC, and patients signed a writ-
ten informed consent before study enrolment.
2.2. Study design and data collection
All IBD patients with and without self-reported joint/back pain, who 
signed informed consent, were seen at the JOINT outpatient clinic at 
study inclusion and at 1 year follow-up. During the 12-month study 
period, patients were asked to complete monthly questionnaires 
assessing IBD disease activity and spine and/or peripheral joint 
scores. When no response was received within 1 week, a reminder 
email or letter was sent out, followed by a telephone call.
 During the baseline visit, a routine medical history was taken and 
data on extra-intestinal manifestations were collected from all partici-
pants, including common IBD-related eye and skin manifestations such 
as acute anterior uveitis and erythema nodosum. The musculoskeletal 
history included back pain, enthesitis, arthritis, and dactylitis. The fam-
ily history included IBD, SpA (including ankylosing spondylitis [AS]), 
acute anterior uveitis, psoriasis, and reactive arthritis. In addition to 
the routine physical examination, a rheumatological examination was 
performed in all IBD patients by a well-trained clinical researcher, 
including a detailed assessment of the number of tender and swol-
len joints. Furthermore, the presence of dactylitis was registered and 
enthesitis was assessed using the Maastricht Ankylosing Spondylitis 
Enthesitis Score [MASES] index.7 Assessment of spinal mobility was 
performed using the modified Schober test, lateral spinal flexion, cervi-
cal rotation, occiput-to-wall distance [OWD], chest expansion, and the 
intermalleolar distance.8 The Bath Ankylosing Spondylitis Metrology 
Index [BASMI] was calculated, ranging from 0–10.9 In the BASMI, the 
tragus-to-wall distance is used and derived from the OWD by adding 
8 cm. The value zero in the OWD is equivalent to a score of zero in 
the BASMI calculation. The higher the BASMI score, the more severe 
the patient’s limitation of axial movement. Spinal disease activity and 
function were assessed using the Bath Ankylosing Spondylitis Disease 
Activity Index [BASDAI]10 and the Bath Ankylosing Spondylitis 
Functional Index [BASFI].11 Laboratory assessments included erythro-
cyte sedimentation rate [ESR] and C-reactive protein [CRP]. Human 
leukocyte antigen-B27 [HLA-B27] was only typed in patients with 
CBP and/or peripheral joint complaints. Radiographs of the pelvis 
[anterior-posterior view], the lumbar and cervical spine [lateral view], 
and the most painful peripheral joints were performed in patients with 
joint/back pain.
Following the baseline assessment, patients were categorised into 
two study groups:
1. Patients with joint/back pain: CBP for ≥ 3 months and/or pJTC 
currently or during the previous year.
2. Patients without joint/back pain: no back pain or pJTC during 
the previous year.
2.3. Definitions
a. Crohn’s disease [CD] disease activity was assessed according to 
the Harvey-Bradshaw Index [HBI]12; ulcerative colitis [UC] dis-
ease activity was assessed using the Simple Clinical Colitis Activ-
ity Index [SCCAI].13 A score > 4 reflects active disease.
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b. Arthralgia was defined as joint pain without swelling; arthritis as 
joint pain with swelling.
c. Overall and nocturnal pain of the spine and peripheral joint pain 
during the previous week were separately scored on an 11-point 
numeric rating scale [NRS] ranging from 0 [no pain] to 10 [worst 
possible pain].14
d. Disease activity of the spine and disease activity of the periph-
eral joints during the previous week were scored, separately, on 
an 11-point NRS where 0 is inactive disease and 10 is extremely 
active disease.
e. Patients were classified as SpA according to the Amor15 European 
Spondyloarthropathy Study Group [ESSG]16 Assessment of Spon-
dyloArthritis international Society [ASAS]17,18 and modified New 
York [mNY] criteria.19
2.4. SpA classifications
In short, the Amor criteria for SpA consist of a scoring system 
of eight clinical features [1–2 points per feature], radiographic 
sacroiliitis [3 points], HLA-B27 [2 points], and a good response 
to non-steroidal anti-inflammatory drugs [NSAIDs] [2 points]. 
IBD is one of the clinical features receiving 2 points. A score of 
6 or more classifies a patient as having SpA. In the ESSG crite-
ria, patients with IBD and inflammatory back pain [according to 
the ESSG standard] and/or arthritis [past or present asymmetrical 
arthritis or arthritis predominantly in the lower limbs] are clas-
sified as SpA. ASAS developed two SpA criteria sets to classify 
patients with predominantly axial SpA [axSpA] and with predom-
inantly peripheral SpA [pSpA]. Patients with IBD and CBP for ≥ 
3 months and age at onset of back pain < 45 years can be classi-
fied as axSpA if sacroiliitis on radiograph or magnetic resonance 
imaging [MRI] is present and/or if HLA-B27 with at least one 
other SpA feature is present. An IBD patient with arthritis [usu-
ally predominantly lower limbs and/or asymmetrical arthritis], 
enthesitis, or dactylitis should be classified as pSpA. According 
to the mNY criteria, patients with AS based on radiographic sac-
roiliitis and the clinical criteria CBP for ≥ 3 months are classified 
as SpA [see Supplementary data available at ECCO-JCC online].
2.5. Statistics
Continuous variables were described with mean ± SD and categori-
cal variables as proportions with percentages. T-tests were used 
for comparing continuous variables among the two study groups 
and Fisher’s exact and chi-square tests were used for compar-
ing categorical variables. Logistic regression models, with joint/
back pain as the dependent variable, were used to assess variables 
associated with joint/back pain in IBD. First, univariate analyses 
were performed for several variables, including age, gender, type 
of IBD, IBD-associated surgery, active IBD [HBI or SCCAI >  4], 
IBD patients visited the IBD




































Figure 1. Patient inclusion flow chart.
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smoking, family history for SpA, and cutaneous, ocular, and joint 
manifestations. Second, variables with a statistical level of p < 0.1 
in the univariate analyses were included in the multivariate analy-
ses. Linear mixed model analyses were performed to investigate 
whether IBD disease activity is associated with a worsening [eg an 
increased score] in the following items throughout follow-up:  1] 
disease activity of the spine; 2] general and nocturnal pain of the 
spine;  3] disease activity of the peripheral joints;  4] general and 
nocturnal pain of the peripheral joints. Patients were included as 
random variables, time points and IBD disease activity as fixed 
variables, and the outcome measures fixed as dependent variables. 




In total, 510 IBD patients completed the questionnaire on joint 
complaints at the IBD outpatient clinic of the LUMC: 321 patients 
with Crohn’s disease [CD], 186 with ulcerative colitis [UC], and 
3 with indeterminate colitis [IC]. Of these, 310 [60.8%] patients 
reported joint complaints: 12% back pain only, 54% pJTC only, 
and 34% both [Figure 1]. The percentage of patients complaining 
about joint pain was higher in CD [65%] compared with UC [49%]. 
Subsequently, since only one clinical researcher was well trained 
in the assessment and examination of joint complaints, inclusion 
was limited to 255 patients [50%]. These 255 IBD patients signed 
Table 1. Clinical and demographic characteristics of the study population at baseline [Visit 1].
IBD with joint/back pain [n = 155] IBD without joint/back pain [n = 100] p-Value
Type of IBD, n
 Crohn’s disease 121 [78.1%] 65 [65.0%] 0.03
 Ulcerative colitis 34 [21.9%] 35 [35.0%]
Male, n 46 [29.7%] 51 [51.0%] 0.001
Age at inclusion [years], mean ± SD 43.4 ± 13.6 42.7 ± 13.5 0.71
Age of IBD onset [years], mean ± SD 27.5 ± 11.3 26.0 ± 10.0 0.28
IBD disease duration [years], mean ± SD 15.4 ± 11.8 16.2 ± 11.0 0.56
Arthropathy onset in relation to IBD diagnosis
  •CBP 84% after/16% before -
  •pJTC 80% after/20% before -
Arthropathy onset after IBD diagnosis [years]
  •CBP in CD[n = 46]/UC[n = 17] 14.7 ± 12.6/17.8 ± 10.5 [ns] -
  •pJTC in CD[n = 86]/UC[n = 26] 11.6 ± 10.5/13.0 ± 9.6 [ns] -
Smoker, n 47 [30.0%] 13 [13.0%] 0.001
Montreal classification: 0.06
Location CD, n n = 121 n = 65
 L1 ileal 34 [28.1%] 12 [18.5%]
 L2 colonic 27 [22.3%] 13 [20.0%]
 L3 ileocolonic 52 [43.0%] 31 [47.7%]
 L4 upper - 2 [3.1%]
 L1-3+L4 8 [6.6%] 7 [10.8%]
Behaviour CD, n 0.07
 B1 non-stricturing/penetrating 77 [63.6%] 32 [49.2%]
 B2 stricturing 24 [19.8%] 14 [21.5%]
 B3 penetrating 20 [16.5%] 19 [29.2%]
 + Perianal disease 37 [30.6%] 18 [27.7%]
Extension UC, n n = 34 n =35 0.23
 E1 ulcerative proctitis 5 [14.7%] 2 [5.7%]
 E2 left-sided UC 13 [38.2%] 10 [28.6%]
 E3 extensive UC [pancolitis] 16 [47.1%] 23 [65.7%]
IBD-related surgery, n 68 [43.9%] 39 [39.0%] 0.44
Family history SpA,a n 45 [29.0%] 29 [29.0%] 1.0
Extra-intestinal manifestations,b n
 Skin 27 [17.4%] 7 [7.0%] 0.04
 Eye 22 [14.2%] 5 [5.0%] 0.02
Current medication use, n
 5-ASA [mesa, sulfa] 24 [15.5%] 27 [27.0%] 0.03
 Steroids 11 [7.1%] 3 [3.0%] 0.16
 Immunosuppressive drugs [Aza/6MP/MTX] 34 [21.9%] 21 [21.0%] 0.86
 Anti-TNF 42 [27.1%] 30 [30.0%] 0.61
 None 44 [28.4%] 19 [19.0%] 0.09
SD, standard deviation; IBD, inflammatory bowel disease; CBP, central back pain; pJTC, peripheral joint complaints; CD, Crohn’s disease; UC, ulcerative colitis; 
SpA, spondyloarthritis; 5-ASA [mesa, sulfa], 5-aminosalicylates [mesalazine, sulfasalizine]; AZA, azathiopurine; 6MP, 6-mercaptopurine; MTX, methotrexate; 
TNF, tumour necrosis factor; ns, not significant.
aFamily history SpA: ankylosing spondylitis, reactive arthritis, psoriasis, IBD, uveitis, all according to the definition of the ASAS criteria.
bSkin: psoriasis, erythema nodosum, pyoderma gangrenosum. Eye: acute anterior uveitis.
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informed consent and attended the multidisciplinary clinic, of whom 
155 [60.1%] were assigned to the study group with joint/back pain, 
whereas 100 [38.8%] patients without joint/back pain served as 
controls. The clinical and demographic characteristics of all patients 
are presented in Table 1. For 80–84% of patients, the onset of CBP 
and pJTC followed the IBD diagnosis and was on average more than 
a decade after diagnosis, with a trend towards pJTC starting a few 
years earlier than CBP [Table 1]. Only 16–20% developed joint/back 
pain prior to the diagnosis of IBD. Patients with IBD and joint/back 
pain were more often diagnosed with CD [p  =  0.03], were more 
frequently female [p = 0.001], were more often smokers [p = 0.001], 
were more likely to have cutaneous manifestations [psoriasis, ery-
thema nodosum, pyoderma gangrenosum] [p  =  0.04], and acute 
anterior uveitis [p = 0.02] compared with patients with IBD without 
joint/back pain. The Montreal classification did not reveal subtypes 
more prone to developing joint/back pain. In addition, previous IBD-
related surgery or a family history of SpA was not associated with 
the development of joint/back pain.
Of the 155 patients with joint/back pain, 80 patients [51.6%] 
reported pJTC only, 13 patients [8.4%] reported CBP only, and 62 
patients [40.0%] reported axial as well as peripheral joint involve-
ment [Table  2]. Over 50% of pJTC patients reported the hand 
[32.5%] and the knee [17.5%] as the most frequently affected joints, 
whereas 80.0% of patients reported involvement of more than one 
joint. At physical examination, 98 [63.2%] patients had ≥ 1 tender 
joint, and 48 [31.0%] patients had ≥ 1 tender pressure point for 
enthesitis. Only 52 IBD patients with evident joint swelling and signs 
of inflammation seen during rheumatological examination or on the 
radiographs were referred to the rheumatologist. Based on physical 
examination performed by the rheumatologist, 15 patients [9.7%] 
were diagnosed with arthritis and all could be classified as showing 
type 1 peripheral joint complaints according to the Oxford criteria. 
In addition, one [0.7%] patient was diagnosed with dactylitis, one 
[0.7%] patient with enthesitis, and two [1.4%] patients with tend-
initis. Following radiographic assessment of all 75 CBP patients, 5 
patients [6.7%] showed sacroiliitis and 1 patient was diagnosed with 
Table 2. Characteristics of 155 inflammatory bowel disease [IBD] patients with self-reported joint and/or back pain.
Chronic back pain [n = 13] Peripheral joint complaints [n = 80] Both [n = 62] p-Value
Type of IBD, n 0.6
 Crohn’s disease 10 [76.9%] 65 [81.3%] 46 [74.2%]
 Ulcerative colitis 3 [23.1%] 15 [18.8%] 16 [25.8%]
Male, n 6 [46.2%] 21 [26.3%] 19 [30.6%] 0.34
Age at inclusion [years], mean ± SD 38.2 ± 13.8 41.9 ± 13.5 46.2 ± 13.2 0.06
Age of IBD onset [years], mean ± SD 27.0 ± 14.0 33.0 ± 11.6 48.0 ± 13.5 0.25
IBD disease duration [years], mean ± SD 21.0 ± 19.8 33.0 ± 77.2 6.0 ± 6.7 0.21
Location [most painful] peripheral joints, n 0.16
 Shoulder - 10 [12.5%] 6 [9.7%]
 Elbow - 10 [12.5%] 2 [3.2%]
 Wrist - 9 [11.3%] 7 [11.3%]
 Hand - 26 [32.5%] 22 [35.5%]
 Hip - 1 [1.3%] 4 [6.5%]
 Knee - 14 [17.5%] 17 [27.4%]
 Ankle - 6 [7.5%] 1 [1.6%]
 Feet - 4 [5.0%] 3 [4.8%]
Distribution, n 0.22
 Monoarticular - 16 [20.0%] 6 [9.8%]
 Oligoarticular - 32 [40.0%] 30 [48.3%]
 Polyarticular - 32 [40.0%] 26 [41.9%]
SpA features, n
 Arthritis a 0 [0.0%] 8 [10.0%] 7 [11.3%] 0.45
 HLA-B27 positive [n = 150] 0 [0.0%] 1 [1.3%] 6 [9.7%] 0.15
 Positive family for SpA 5 [38.5%] 20 [25.0%] 18 [29.0%] 0.59
 Inflammatory back pain 5 [38.5%] - 37 [59.7%] 0.001
 Psoriasisa 2 [15.4%] 7 [8.8%] 5 [8.1%] 0.71
 Dactylitisa 0 [0.0%] 1 [1.3%] 0 [0.0%] 0.62 
 Enthesitisa 0 [0.0%] 0 [0.0%] 1 [1.6%] 0.47 
 Uveitisa 1 [7.7%] 10 [12.5%] 9 [14.5%] 0.78 
 Preceding infection 0 [0.0%] 0 [0.0%] 0 [0.0%] -
 Alternating buttock pain 3 [23.1%] 0 [0.0%] 22 [35.5%] 0.001
 Good response to NSAIDs [n = 44] 2 [15.4%] 20 [25.0%] 11 [17.7%] 0.57
 Sacroiliitis on radiograph 1 [7.7%] 0 [0.0%] 4 [6.5%] 0.06
 Sacroiliitis on MRI [n = 0] - - - -
Total SpA features, n [mean] 22 [1.7] 108 [1.4] 141 [2.3]
Patients classified with SpAb, n 6 [46.2%] 14 [17.5%] 43 [69.4%] 0.001
Elevated CRP, n 1 [7.7%] 15 [18.8%] 11 [17.7%] 0.64
Elevated ESR [n = 153], n 2 [15.4%] 26 [32.5%] 10 [16.1%] 0.60
SD, standard deviation; SpA, spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; MRI, magnetic resonance imaging; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate.
aAll confirmed by a specialist.
bBased on one of the different SpA criteria.
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diffuse idiopathic skeletal hyperostosis [DISH] of the lumbar spine. 
In total, 136/155 [87.7%] patients with self-reported joint/back pain 
were diagnosed with arthralgia. The mean BASDAI and mean BASFI 
of CBP patients were 3.1 [SD 1.9] and 2.2 [SD 1.9], respectively. The 
mean BASMI in pJTC patients with CBP was higher compared with 
pJTC patients without CBP: 1.7 [SD 0.9] vs. 1.4 [SD 0.8], p = 0.03.
Univariate analysis showed that CD [p  = 0.02], female gender 
[p = 0.001], smoking [p = 0.002], IBD disease activity [p < 0.001], 
cutaneous manifestations [p  =  0.02], and acute anterior uveitis 
[p  = 0.03] were associated with an increased odds ratio [OR] for 
joint/back pain [Table 3]. In the multivariate analysis, the variables 
female gender (OR 1.97 [95% CI 1.10–3.53], p = 0.02), smoking 
(2.28 [95% CI 1.10–4.75], p = 0.03) and IBD disease activity (OR 
4.07 [95% CI 2.23–7.45], p < 0.001 remained independently associ-
ated with IBD joint/back pain.
3.2. Classification
Overall, IBD patients with CBP had on average 1.7 SpA features, 
pJTC patients 1.4, and IBD patients with both CBP and pJTC had 
on average 2.3 different SpA features. Based on the various SpA 
features [Table 2], 155 patients with joint/back pain were classified 
according to the SpA criteria sets. In total, 28 out of the 155 patients 
[18.1%] conformed with more than one classification criteria set, 
and 63 [40.6%] patients fulfilled any of the SpA criteria sets: 32 
[20.6%] patients fulfilled the Amor criteria, and 52 [33.5%] patients 
fulfilled the ESSG criteria, including 37 [71.2%] in the inflammatory 
back pain arm, 10 in the peripheral arm, and 5 in both arms. In all, 
19 [12.3%] patients fulfilled the recently developed ASAS criteria, 6 
met the axSpA criteria, and 15 met the pSpA criteria [Figure 2]. Four 
[2.6%] patients fulfilled the mNY criteria for AS. These four patients 
also fulfilled the Amor, the ESSG, and the ASAS criteria for axial 
SpA. There were no differences in gender and type of IBD between 
patients fulfilling any of the SpA criteria sets compared with those 
who did not fulfil any of the SpA criteria sets [data not shown].
3.3. Follow-up
In total, 242/255 [94.9%] patients were seen at the 12-month visit 
of the joint outpatient clinic [Figure 3]: 98 patients without and 
144 patients with joint/back pain. Five of 98 patients without joint 
complaints at baseline developed joint complaints without symp-
toms or signs of disease activity, whereas 12 of 144 patients with 
joint complaints at baseline reported a cessation of joint/back pain 
at 12 months. Five of the 136 [3.7%] patients with arthralgia at 
Visit 1 developed arthritis, 1/136 [0.7%] developed enthesitis, and 
1/136 [0.7%] developed tendinitis during the 12-month follow-up 
period.
A total of 245/255 [96.1%] patients completed all 12 ques-
tionnaires to assess IBD disease activity and spine and/or periph-
eral joint scores: 148/155 patients with and 97/100 patients 
without joint/back pain. A total of 122/148 [82.4%] IBD patients 
with joint/back pain completed ≥ 7 questionnaires in which they 
Table 3. Logistic regression analyses of inflammatory bowel disease [IBD] patients, with the presence of arthropathies as the dependent 
variable.
Variable n Univariate Multivariate
OR [95% CI] p-Value OR [95% CI] p-Value
Age [years] Visit 1 255 1.0 [0.99–1.02] 0.71 -
Gender
 Male [ref.] 97
 Female 158 2.47 [1.46–4.16] 0.001 1.97 [1.10–3.53] 0.02
Type of IBD
 UC [ref] 69
 CD 186 1.92 [1.10–3.36] 0.02 1.25 [0.66–2.35] 0.5
Smoking
 No [ref.] 195
 Yes 60 2.91 [1.48–5.73] 0.002 2.28 [1.10–4.75] 0.03
Active IBD diseasea
 No [ref.] 153
 Yes 103 4.61 [2.57–8.26] <0.001 4.07 [2.23–7.45] <0.001
IBD-related surgery
 No [ref.] 148
 Yes 107 1.22 [0.73–2.04] 0.44 -
Cutaneous manifestationsb
 No [ref.] 221
 Yes 34 2.80 [1.17–6.71] 0.02 1.74 [0.66–4.56] 0.26
Ocular manifestationc
 No [ref.] 228
 Yes 27 3.14 [1.15–8.6] 0.03 1.83 [0.61–5.48] 0.28
Family history SpAd
 No [ref.] 181
 Yes 74 1.0 [0.57–1.74] 1.0 -
OR, odds ratio; CI, confidence interval; UC, ulcerative colitits; CD, Crohn’s disease; SpA, spondyloarthritis.
aHarvey-Bradshaw Index or Simple Clinical Colitis Activity Index score > 4.
bCutaneous manifestations: psoriasis, erythema nodosum, pyoderma gangrenosum.
cOcular manifestation: acute anterior uveitis.
dFamily history SpA, ankylosing spondylitis, reactive arthritis, psoriasis, IBD, uveitis, all according to the definition of the ASAS criteria.
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reported the course of their IBD disease activity and joint com-
plaints in the 12-month follow-up. Of these 122 patients with 
joint/back pain in the follow-up period, IBD disease activity was 
continuously in clinical remission in 31.1% of patients, compared 
with 36.9% with continuous IBD disease activity and 32.0% with 
intermittent IBD disease activity. Smokers with CD appeared to 
be prone to developing continuous IBD disease activity, although 
the difference was not significant [p  =  0.08]. In patients with 
joint/back pain, the HBI scores for general well-being [p = 0.002], 
abdominal pain [p = 0.025], diarrhoea [p < 0.001], aphthous ulcers 
[p = 0.03], and the SCCAI score on nocturnal pain [p < 0.001], 
all affected IBD disease activity compared with IBD patients in 
continuous clinical remission. Patients with continuous IBD dis-
ease activity were more likely to be referred to the rheumatologist 
[p = 0.04] for their joint complaints.
The linear mixed model analyses demonstrated that IBD dis-
ease activity was significantly associated with higher scores for 
disease activity of the spine, pain and nocturnal pain of the spine, 
disease activity of the peripheral joints, and pain and nocturnal 
pain of the peripheral joints, over time, with a range of regres-
sion coefficients estimated between 0.47–1.52 [all p  <  0.05]. 
Thereafter, we also included type of IBD and gender as fixed 
factors. CD was only significantly associated with higher scores 
for pain and nocturnal pain of the peripheral joints [regression 
coefficients ranged 0.96–1.00, p < 0.05]. Gender had no signifi-
cant effect.
4. Discussion
Since gastroenterologists are not used to the diagnosis and manage-
ment of joint/back pain, a multidisciplinary approach in cooperation 
with rheumatologists is necessary.
 In this prospective study, 255 IBD patients attended the multidis-
ciplinary IBD JOINT outpatient clinic, including 155 with and 100 
without joint/back pain. The patients in the former category reported 
joint pain, back pain, or both, and we characterised these complaints 
in depth. In our cohort, IBD patients reporting joint/back pain were 
more likely to be diagnosed with CD, female, smokers, and to show 
cutaneous manifestations and acute anterior uveitis, compared with 
patients without arthropathies. Female gender, smoking, and IBD 
disease activity were independently associated with joint/back pain 















Not fulfulling these criteria
Figure  2. Venn diagram representing the overlap between the various 
classification criteria for SpA. Patients were classified as spondyloarthritis 
[SpA] according to the Amor,15 European Spondyloarthropathy Study Group 
[ESSG],16 Assessment of SpondyloArthritis international Society [ASAS] 
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Figure 3. Follow-up inflammatory bowel disease [IBD] patients.
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with pain and disease activity of the spine and peripheral joints over 
time. Although joint/back pain is frequently encountered in IBD pat
ients,1,2,3,14,20,21 only 12.3% fulfilled the ASAS criteria for SpA, which 
are most often used in clinical trials.22 During the 12-month follow-
up, the majority of patients showed no change in the presence or 
absence of joint/back pain. Based on an HBI or SCCAI score above 
4, approximately 37% of the joint/back pain patients reported con-
tinuous IBD disease activity. A possible explanation for the high pro-
portion described in previous studies23,24,25 is that the bulk of the HBI 
score is due to diary card items [pain, diarrhoea, and general well-
being]. Because the remaining index items [arthralgia, for example] 
make a proportionately smaller contribution, this may eventually 
lead to artificially elevated HBI scores. Van der Have et al. showed 
in this cohort that joint/back pain in IBD patients has a significant 
negative impact on quality of life [QoL] and work productivity. This 
difference remained significant during the follow-up of 12 months.26
Gastroenterologists should differentiate SpA patients from non-
SpA patients, to make a distinction between the patients that should 
be referred to a rheumatologist and the patients that should remain 
under supervision of the gastroenterologist. This differentiation may 
be aided through the use of classification criteria based on the SpA 
features. Although classification criteria are not intended for use to 
diagnose SpA in clinical practice, the value of applying classification 
criteria is to distinguish typical cases of a particular disease using a 
standardised diagnostic process. Items in classification criteria reflect 
the essential features of a disease.27
Different SpA criteria were evaluated in this study and the 
finding that more patients complied with the ESSG criteria com-
pared with the ASAS and Amor criteria can be attributed to the 
high number of IBD patients fulfilling the inflammatory back pain 
criteria according to the ESSG criteria set. Recent studies by van 
den Berg et al.27,28 reported that the ASAS criteria for SpA outper-
formed the ESSG and Amor criteria. However, this is in contrast 
with the results described by Cheung et al.29, where the ASAS cri-
teria failed to perform better in comparison with the Amor and 
ESSG criteria. A possible explanation for these opposing results 
is the difference in disease duration in the described cohorts. The 
longer the disease duration, the more likely it is that symptoms 
develop.30
 In our opinion, the ASAS criteria represent the most practical 
system with which to classify axial and peripheral SpA and are thus 
particularly applicable in the clinic because, based on this approach, 
all the subtypes of SpA will be recognised as distinct disease. In total, 
12.3% of patients fulfilled the ASAS criteria for axial and peripheral 
SpA and should be referred to a rheumatologist. However, the num-
ber of patients classified as having axial SpA by the ASAS criteria is 
probably an underestimate in this study, because the axial SpA has 
























Other SpA fetures: IBP, enthesitis,
dactylitis, uveitis, positive family
history, IBD, alternating buttock
pain, psoriasis, arthritis, good
response to NSAIDs, elevated
ESR/CRP 
HLA-B27
Figure 4. Proposal for the referral algorithm for suspected axial spondyloarthritis in patients with inflammatory bowel disease [IBD]. The first step for the 
gastroenterologist is to refer all patients with chronic back pain [CBP] to the radiologist to examine whether sacroiliitis can be found on the anterior-posterior 
[AP] plain radiograph of the pelvis. Conventional radiography of the sacroiliac [SI] joints is recommended as first imaging method but, in certain cases such as 
young patients and those with a short symptom duration, magnetic resonance imaging [MRI] is an alternative as first method.38 The patients with an indicated 
sacroiliitis on the radiograph should be referred to the rheumatologist. In patients who are not positive for sacroiliitis of the pelvis, the presence of different 
SpA features should be ascertained. A patient with ≥ 4 SpA features should be referred to the rheumatologist and has a high probability of having axial SpA. 
Patients with fewer than four SpA features should undergo human leukocyte antigen –B27 [HLA-B27] testing. Patients with a positive HLA-B27 test and 2–3 
SpA features possibly have axial SpA and thus will be referred to the rheumatologist. Patients with a positive HLA-B27 test and the presence of ≤ 1 SpA feature 
should undergo MRI.31
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 Gastroenterologists need an efficient referral algorithm that can be 
applied to IBD patients with CBP. In total, 75 patients had CBP, although 
not all of them were suspicious for axial SpA. Based on the Berlin algo-
rithm,31 we propose a modified referral algorithm for IBD patients with 
suspected axial SpA, which can be utilised by gastroenterologists in the 
clinic to distinguish patients with a high probability of axial SpA from 
low-risk patients [Figure 4]. This proposed algorithm should be vali-
dated in future studies in an IBD cohort with joint/back pain.
 Orchard et al. proposed the Oxford criteria for IBD patients with 
peripheral joint complaints. These criteria are often used by gastroen-
terologists, since they are unfamiliar with the diagnosis and manage-
ment of joint/back pain in patients with IBD.5 However, rather than 
using the Oxford criteria which mainly focus on peripheral joint com-
plaints, joint/back pain in IBD patients is best categorised into SpA and 
non-SpA. This is also emphasised in our cohort, with only 15 patients 
[9.7%] fulfilling the Oxford criteria. Use of the Oxford criteria increases 
the chance that SpA patients with an axial component will be neglected.
 Patients who do not fulfil the arthritis criteria can be classified as 
having arthralgia. Like most of the IBD patients with joint/back pain, 
these patients remain under the supervision of a gastroenterologist. 
As few gastroenterologists have the necessary expertise to correctly 
manage joint/back pain, an arthralgia treatment algorithm is also 
needed. Joint pain influences patient QoL and a better understand-
ing of disease aetiology contributes to a better QoL.26 Therefore, 
patients with arthralgia should be informed and educated about 
their symptoms. For example, smoking is independently associated 
with joint/back pain, thus patients should be aware that smoking 
increases the risk of development of joint complaints. Besides pro-
viding adequate information, effective interventions should be rec-
ommended. Physiotherapy is one intervention that can maintain or 
stimulate the flexibility of the joints without adverse effects. Studies 
have demonstrated the effectiveness of physiotherapy in patients 
with joint/back pain and the subsequent improvement of mobility of 
the joints.32,33,34 Due to the common inflammatory pathways and the 
role of cytokines in IBD and arthropathies, IBD-related medication 
may also have a positive effect on joint complaints.35
 We have shown that joint/back pain is correlated with IBD dis-
ease activity. Thus, a ‘treat to target’ strategy, including mucosal 
healing, could prove valuable in controlling symptoms of joint/back 
pain.36,37 Future studies should evaluate the impact of mucosal heal-
ing on IBD-related joint/back pain.
 In conclusion, proper classification and management of joint/
back pain is a challenging task for gastroenterologists. Classification 
should be performed using existing rheumatological standards to fur-
ther enhance multidisciplinary management in SpA-positive patients. 
Future approaches to IBD-associated joint/back pain should include 
care pathways guided by treatment algorithms applicable to the 
daily practice of the gastroenterologist.
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